<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> ....
Awaiting price reaction for this filing.
Ajanta Pharma Limited has submitted its annual disclosure under the SEBI circular on fund raising by Large Corporates (dated November 26, 2018). The company has confirmed that it does not qualify as a 'Large Corporate' under the framework's applicability criteria. As per Annexure A, Ajanta Pharma reported zero outstanding borrowings as of March 31, 2025. The company holds the highest short-term credit rating of CARE A1+ from CARE Ratings Limited. NSE has been named as the stock exchange where any potential fine for shortfall in mandatory borrowing would be paid, though this is purely procedural since the company is not a Large Corporate.
This is a routine compliance filing with no material impact on shareholders. The nil outstanding borrowing and top-tier CARE A1+ credit rating actually reflect strong financial health, indicating Ajanta Pharma is effectively debt-free and enjoys the highest confidence from credit agencies.